| European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update |
198 |
| European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update |
179 |
| Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2 |
163 |
| European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update |
150 |
| Epidemiology of Renal Cell Carcinoma |
138 |
| Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study |
101 |
| Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018 |
92 |
| Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 |
77 |
| Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators |
70 |
| Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology |
67 |
| Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial |
66 |
| Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers |
60 |
| Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma |
57 |
| Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial |
56 |
| Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System) |
52 |
| Genomic Markers in Prostate Cancer Decision Making |
49 |
| Impact of Ga-68-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis |
48 |
| Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions |
47 |
| A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer |
47 |
| Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors |
43 |
| Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma |
42 |
| EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence |
42 |
| A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer |
41 |
| Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial |
41 |
| Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes |
41 |
| Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial |
39 |
| The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies |
39 |
| Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review |
39 |
| Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Lu-177-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer |
38 |
| Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis |
36 |
| Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis |
35 |
| Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions |
35 |
| Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10 ng/ml at Initial Biopsy |
34 |
| Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations |
34 |
| A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment |
34 |
| Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging |
34 |
| Abiraterone in High- and Low-risk Metastatic Hormone-sensitive Prostate Cancer |
33 |
| Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? |
32 |
| Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants |
32 |
| Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations |
32 |
| Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube |
32 |
| Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018 |
31 |
| Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial |
30 |
| Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma |
30 |
| Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy |
30 |
| Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract |
30 |
| Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS) |
30 |
| Managing Nonmetastatic Castration-resistant Prostate Cancer |
30 |
| Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer |
29 |
| Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer |
29 |
| High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility |
29 |
| Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis |
29 |
| Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018 |
28 |
| Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review |
28 |
| Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide |
28 |
| Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry |
28 |
| Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis |
27 |
| Efficacy, Predictive Factors, and Prediction Nomograms for Ga-68-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy |
27 |
| A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies |
27 |
| Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer |
26 |
| (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer |
26 |
| Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies |
25 |
| Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression |
25 |
| Robot-assisted Kidney Transplantation: The European Experience |
25 |
| The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer |
25 |
| Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019 |
24 |
| Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group) |
24 |
| Compound Genomic Alterations of TP PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer |
24 |
| Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators |
24 |
| Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers |
24 |
| EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study) |
24 |
| Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study |
23 |
| Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review |
23 |
| Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results |
23 |
| The Microbiome and Genitourinary Cancer: A Collaborative Review |
23 |
| Vibegron, a Novel Potent and Selective beta(3)-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study |
23 |
| Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer |
23 |
| The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability |
23 |
| The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review |
23 |
| Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review |
23 |
| Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity |
22 |
| Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We There Yet? A Systematic Review |
22 |
| The Long Noncoding RNA TTTY Which Is Located on the Y Chromosome, Promotes Prostate Cancer Progression by Sponging let-7 |
22 |
| Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer |
22 |
| Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer |
22 |
| Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy |
22 |
| Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes |
22 |
| Robotic Urologic Surgical Interventions Performed with the Single Port Dedicated Platform: First Clinical Investigation |
22 |
| Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency |
21 |
| Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study |
21 |
| The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management |
21 |
| Safety of Vaginal Mesh Surgery Versus Laparoscopic Mesh Sacropexy for Cystocele Repair: Results of the Prosthetic Pelvic Floor Repair Randomized Controlled Trial |
21 |
| Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses |
21 |
| Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology |
20 |
| Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting |
20 |
| Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial |
20 |
| Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion |
20 |
| Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer |
20 |
| Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer |
19 |
| Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy |
19 |
| A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease |
19 |
| A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy |
19 |
| Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer |
19 |
| Utilising the Delphi Process to Develop a Proficiency-based Progression Train-the-trainer Course for Robotic Surgery Training |
19 |
| Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer |
19 |
| The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment |
18 |
| Three-dimensional Elastic Augmented-reality Robot-assisted Radical Prostatectomy Using Hyperaccuracy Three-dimensional Reconstruction Technology: A Step Further in the Identification of Capsular Involvement |
18 |
| Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes |
18 |
| Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging |
18 |
| Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma |
18 |
| Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes |
18 |
| Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis |
18 |
| Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma |
18 |
| Hyperaccuracy Three-dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping During Robot-assisted Partial Nephrectomy for Complex Renal Masses |
18 |
| A Prospective Cohort Study of Postdischarge Opioid Practices After Radical Prostatectomy: The ORIOLES Initiative |
17 |
| Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy |
17 |
| Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery |
17 |
| Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies |
17 |
| Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for >= 24 weeks in Europe |
17 |
| Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer |
17 |
| Ischemia Techniques in Nephron-sparing Surgery: A Systematic Review and Meta-Analysis of Surgical, Oncological, and Functional Outcomes |
16 |
| Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II) |
16 |
| Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis |
16 |
| Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications |
16 |
| Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial |
16 |
| Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence |
16 |
| Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling |
16 |
| Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis |
16 |
| Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer |
16 |
| First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium |
16 |
| Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer |
15 |
| A Systematic Review and Meta-analysis Comparing the Efficacy of Nonsteroidal Anti-inflammatory Drugs, Opioids, and Paracetamol in the Treatment of Acute Renal Colic |
15 |
| Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial |
15 |
| The Learning Curve for Robot-assisted Partial Nephrectomy: Impact of Surgical Experience on Perioperative Outcomes |
15 |
| Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201) |
15 |
| Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights |
15 |
| Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media |
15 |
| Impact of Three-dimensional Printing in Urology: State of the Art and Future Perspectives. A Systematic Review by ESUT-YAUWP Group |
15 |
| Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review |
15 |
| Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection |
15 |
| Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA) |
15 |
| Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates |
15 |
| Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer |
14 |
| A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma |
14 |
| Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019 |
14 |
| Robotic Intracorporeal Padua Ileal Bladder: Surgical Technique, Perioperative, Oncologic and Functional Outcomes |
14 |
| Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer |
14 |
| Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium |
14 |
| Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial |
14 |
| Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer |
14 |
| A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts |
14 |
| Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade |
14 |
| Augmented Bladder Tumor Detection Using Deep Learning |
14 |
| A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings |
14 |
| The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential |
13 |
| Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer |
13 |
| Genomic Differences Between Primary and Secondary Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy |
13 |
| Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy |
13 |
| Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy |
13 |
| Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel |
13 |
| The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer |
13 |
| Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial |
13 |
| Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects |
13 |
| Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial |
13 |
| Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer |
13 |
| The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification |
13 |
| Procedure-specific Risks of Thrombosis and Bleeding in Urological Cancer Surgery: Systematic Review and Meta-analysis |
13 |
| Robot-assisted Retrohepatic Inferior Vena Cava Thrombectomy: First or Second Porta Hepatis as an Important Boundary Landmark |
13 |
| Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients |
12 |
| Robotic Ureteral Reconstruction Using Buccal Mucosa Grafts: A Multi-institutional Experience |
12 |
| Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel |
12 |
| Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors |
12 |
| Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma |
12 |
| Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer |
12 |
| Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry |
12 |
| Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension |
12 |
| Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial |
12 |
| Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review |
12 |
| Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes |
12 |
| Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases |
12 |
| Detrusor Underactivity and the Underactive Bladder: A Systematic Review of Preclinical and Clinical Studies |
12 |
| Robot-assisted AMS-800 Artificial Urinary Sphincter Bladder Neck Implantation in Female Patients with Stress Urinary Incontinence |
11 |
| The ERUS Curriculum for Robot-assisted Partial Nephrectomy: Structure Definition and Pilot Clinical Validation |
11 |
| Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma |
11 |
| Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer |
11 |
| Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy |
11 |
| Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene |
11 |
| Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA |
11 |
| Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature |
11 |
| Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy |
11 |
| Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells |
11 |
| Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men |
11 |
| Ride the Green Light: Indocyanine Green-marked Off-clamp Robotic Partial Nephrectomy for Totally Endophytic Renal Masses |
11 |
| Positron Emission Tomography/Computed Tomography with Zr-89-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion |
11 |
| First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis |
11 |
| Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review |
11 |
| Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients |
10 |
| Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results |
10 |
| Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma |
10 |
| Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival |
10 |
